Abstract
In this issue of Blood, Eichhorst and colleagues report on the results of the German CLL Study Group (GCLLSG) CLL5 study.1 The importance of this randomized trial is that it restricted enrollment to more elderly patients who are the most representative of the population who have this disease.
Cite
CITATION STYLE
APA
Gribben, J. G. (2009, October 15). One step back but 2 steps forward. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2009-08-234146
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free